Therefore, Menin-inhibitors are currently a particularly promising group of compounds for selective, potent, and minimally toxic targeted therapy in MLL-rearranged and NPM1c-mutated leukemia and other MLL1-dependent dependent cancer types. This evidence concerns the gene KMT2A and cancer.